Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates

M. K. Brawer, Raymond B Nagle, W. Pitts, F. Freiha, S. L. Gamble

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Postirradiation prostatic biopsy is believed by many to be the best measure of radiation effectiveness in prostatic cancer. Therapeutic irradiation may induce prostatic glandular atypia, which in its severe form can be confused with persistent adenocarcinoma on prostatic biopsies. In the current study, 37 postirradiation prostate biopsy specimens were evaluated by immunohistochemistry using a specific monoclonal anticytokeratin antibody (KA1) that reacts with the basal cells of normal or hyperplastic glands, but is nonreactive with the lumenal cells or with prostatic carcinoma cells. Persistent carcinoma was observed in 19 cases in which antibody staining was absent. The noncarcinomatous glands retained reactivity, but this reactivity appeared in a new and previously undescribed pattern. The irradiated lesion was characterized by cellular pleomorphisism, with enlargement of nuclei and loss of polarity. The immunoreactivity was seen in the enlarged basal cells and was seen to focally extend to involve the lumenal cell layer. In five of 37 cases, glands were seen that were so atypical on the routinely stained sections that a distinction from cancer could not be made. These same glands in the adjacent section reacted with KA1 in each case allowing us to conclude that the changes were benign. We conclude that the interpretation of postirradiation prostatic biopsy specimens may be aided by immunohistochemistry with this anticytokeratin antibody.

Original languageEnglish (US)
Pages (from-to)454-460
Number of pages7
JournalCancer
Volume63
Issue number3
StatePublished - 1989

Fingerprint

Keratins
Prostate
Adenocarcinoma
Biopsy
Immunohistochemistry
Carcinoma
Antibodies
Prostatic Neoplasms
Monoclonal Antibodies
Radiation
Staining and Labeling
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. / Brawer, M. K.; Nagle, Raymond B; Pitts, W.; Freiha, F.; Gamble, S. L.

In: Cancer, Vol. 63, No. 3, 1989, p. 454-460.

Research output: Contribution to journalArticle

Brawer, MK, Nagle, RB, Pitts, W, Freiha, F & Gamble, SL 1989, 'Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates', Cancer, vol. 63, no. 3, pp. 454-460.
Brawer, M. K. ; Nagle, Raymond B ; Pitts, W. ; Freiha, F. ; Gamble, S. L. / Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. In: Cancer. 1989 ; Vol. 63, No. 3. pp. 454-460.
@article{4d27fc2d86a742df81d855663c405568,
title = "Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates",
abstract = "Postirradiation prostatic biopsy is believed by many to be the best measure of radiation effectiveness in prostatic cancer. Therapeutic irradiation may induce prostatic glandular atypia, which in its severe form can be confused with persistent adenocarcinoma on prostatic biopsies. In the current study, 37 postirradiation prostate biopsy specimens were evaluated by immunohistochemistry using a specific monoclonal anticytokeratin antibody (KA1) that reacts with the basal cells of normal or hyperplastic glands, but is nonreactive with the lumenal cells or with prostatic carcinoma cells. Persistent carcinoma was observed in 19 cases in which antibody staining was absent. The noncarcinomatous glands retained reactivity, but this reactivity appeared in a new and previously undescribed pattern. The irradiated lesion was characterized by cellular pleomorphisism, with enlargement of nuclei and loss of polarity. The immunoreactivity was seen in the enlarged basal cells and was seen to focally extend to involve the lumenal cell layer. In five of 37 cases, glands were seen that were so atypical on the routinely stained sections that a distinction from cancer could not be made. These same glands in the adjacent section reacted with KA1 in each case allowing us to conclude that the changes were benign. We conclude that the interpretation of postirradiation prostatic biopsy specimens may be aided by immunohistochemistry with this anticytokeratin antibody.",
author = "Brawer, {M. K.} and Nagle, {Raymond B} and W. Pitts and F. Freiha and Gamble, {S. L.}",
year = "1989",
language = "English (US)",
volume = "63",
pages = "454--460",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates

AU - Brawer, M. K.

AU - Nagle, Raymond B

AU - Pitts, W.

AU - Freiha, F.

AU - Gamble, S. L.

PY - 1989

Y1 - 1989

N2 - Postirradiation prostatic biopsy is believed by many to be the best measure of radiation effectiveness in prostatic cancer. Therapeutic irradiation may induce prostatic glandular atypia, which in its severe form can be confused with persistent adenocarcinoma on prostatic biopsies. In the current study, 37 postirradiation prostate biopsy specimens were evaluated by immunohistochemistry using a specific monoclonal anticytokeratin antibody (KA1) that reacts with the basal cells of normal or hyperplastic glands, but is nonreactive with the lumenal cells or with prostatic carcinoma cells. Persistent carcinoma was observed in 19 cases in which antibody staining was absent. The noncarcinomatous glands retained reactivity, but this reactivity appeared in a new and previously undescribed pattern. The irradiated lesion was characterized by cellular pleomorphisism, with enlargement of nuclei and loss of polarity. The immunoreactivity was seen in the enlarged basal cells and was seen to focally extend to involve the lumenal cell layer. In five of 37 cases, glands were seen that were so atypical on the routinely stained sections that a distinction from cancer could not be made. These same glands in the adjacent section reacted with KA1 in each case allowing us to conclude that the changes were benign. We conclude that the interpretation of postirradiation prostatic biopsy specimens may be aided by immunohistochemistry with this anticytokeratin antibody.

AB - Postirradiation prostatic biopsy is believed by many to be the best measure of radiation effectiveness in prostatic cancer. Therapeutic irradiation may induce prostatic glandular atypia, which in its severe form can be confused with persistent adenocarcinoma on prostatic biopsies. In the current study, 37 postirradiation prostate biopsy specimens were evaluated by immunohistochemistry using a specific monoclonal anticytokeratin antibody (KA1) that reacts with the basal cells of normal or hyperplastic glands, but is nonreactive with the lumenal cells or with prostatic carcinoma cells. Persistent carcinoma was observed in 19 cases in which antibody staining was absent. The noncarcinomatous glands retained reactivity, but this reactivity appeared in a new and previously undescribed pattern. The irradiated lesion was characterized by cellular pleomorphisism, with enlargement of nuclei and loss of polarity. The immunoreactivity was seen in the enlarged basal cells and was seen to focally extend to involve the lumenal cell layer. In five of 37 cases, glands were seen that were so atypical on the routinely stained sections that a distinction from cancer could not be made. These same glands in the adjacent section reacted with KA1 in each case allowing us to conclude that the changes were benign. We conclude that the interpretation of postirradiation prostatic biopsy specimens may be aided by immunohistochemistry with this anticytokeratin antibody.

UR - http://www.scopus.com/inward/record.url?scp=0024499192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024499192&partnerID=8YFLogxK

M3 - Article

C2 - 2463873

AN - SCOPUS:0024499192

VL - 63

SP - 454

EP - 460

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -